Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
- Second quarter total net product sales of $242.0 million, up 46% year-over-year
August 06, 2024 04:05 PM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024.
“In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential growth in DAYBUE net sales,” said Steve Davis, Chief Executive Officer. “Additionally, we are advancing enrollment in our Phase 3 trial in Prader-Willi syndrome and our Phase 2 / Phase 3 program in Alzheimer’s disease psychosis. With two successful commercial products, a strong pipeline of late and early-stage assets and a growing cash balance, Acadia is in a strong position to support our long-term growth.”
Company Updates
- The journal Med published clinical data from two open-label extension studies, LILAC-1 and LILAC-2, which showed that patients treated with DAYBUE™ (trofinetide) who completed these studies experienced improvement in Rett syndrome symptoms as measured by the Rett Syndrome Behaviour Questionnaire (RSBQ).
- Presented interim data from the open-label real-world LOTUS™ study at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting. LOTUS is an ongoing, open-label caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE.
https://www.businesswire.com/news/home/20240806318039/en/
- Forums
- ASX - By Stock
- NEU
- Acadia
Acadia, page-728
-
- There are more pages in this discussion • 163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.02 |
Change
0.080(0.62%) |
Mkt cap ! $1.664B |
Open | High | Low | Value | Volume |
$13.23 | $13.35 | $12.99 | $5.557M | 423.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1588 | $13.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.06 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1588 | 13.010 |
2 | 1422 | 13.000 |
2 | 3500 | 12.980 |
4 | 4561 | 12.960 |
5 | 5049 | 12.950 |
Price($) | Vol. | No. |
---|---|---|
13.060 | 1000 | 1 |
13.070 | 1709 | 2 |
13.080 | 2082 | 1 |
13.100 | 2082 | 1 |
13.120 | 2082 | 1 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online